Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunization
New immunization study findings recently were published by A. Jorritsma and co-researchers
May 28th, 2008
"Approaches for T-cell-based immunotherapy that have shown substantial effects in clinical trials are generally based on the adoptive transfer of high numbers of antigen-specific cells, and the success of these approaches is thought to rely on the high magnitude of the tumor-specific T-cell responses that are induced. In this study, we aimed to develop strategies that also yield a T-cell repertoire that is highly skewed toward tumor recognition but do not rely on ex vivo generation of tumor-specific T cells," scientists in Netherlands report. "To this end, the tumor-specific T-cell repertoire was first expanded by DNA vaccination and then infused into irradiated...
Source: Vaccine Weekly (2008-05-28)
|
